Keros Therapeutics Inc (KROS)

$32.12

+0.55

(+1.74%)

Market is closed - opens 7 PM, 27 Sep 2023

Insights on Keros Therapeutics Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 91.4% return, outperforming this stock by 100.5%

Performance

  • $31.17
    $32.85
    $32.12
    downward going graph

    2.96%

    Downside

    Day's Volatility :5.11%

    Upside

    2.22%

    downward going graph
  • $31.17
    $59.96
    $32.12
    downward going graph

    2.96%

    Downside

    52 Weeks Volatility :48.02%

    Upside

    46.43%

    downward going graph

Returns

PeriodKeros Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-20.53%
-0.9%
0.0%
6 Months
-23.03%
1.5%
1.0%
1 Year
-9.09%
7.1%
6.4%
3 Years
-37.61%
25.9%
19.9%

Highlights

Market Capitalization
1.1B
Book Value
$11.0
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-4.69
Wall Street Target Price
90.25
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-30.05%
Return On Equity TTM
-47.09%
Revenue TTM
20.0M
Revenue Per Share TTM
0.82
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
-87.3M
EBITDA
-139.5M
Diluted Eps TTM
-4.69
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-5.26
EPS Estimate Next Year
-5.26
EPS Estimate Current Quarter
-1.34
EPS Estimate Next Quarter
-1.36

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Keros Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 180.98%

Current $32.12
Target $90.25

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Keros Therapeutics Inc
Keros Therapeutics Inc
-9.8%
-23.03%
-9.09%
-37.61%
-37.61%
Moderna, Inc.
Moderna, Inc.
-13.8%
-33.86%
-19.73%
39.08%
427.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.18%
1.46%
19.77%
45.55%
105.03%
Novo Nordisk A/s
Novo Nordisk A/s
-2.09%
18.67%
91.43%
165.4%
285.43%
Seagen, Inc.
Seagen, Inc.
4.8%
8.3%
59.7%
13.46%
176.24%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.03%
14.01%
23.51%
31.36%
85.35%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Keros Therapeutics Inc
Keros Therapeutics Inc
NA
NA
NA
-5.26
-0.47
-0.3
0.0
11.0
Moderna, Inc.
Moderna, Inc.
35.31
35.31
0.0
-3.66
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
21.73
21.73
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
42.99
42.99
2.03
1.65
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.52
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
27.12
27.12
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Keros Therapeutics Inc
Keros Therapeutics Inc
Buy
$1.1B
-37.61%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$37.4B
427.53%
35.31
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$90.4B
105.03%
21.73
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$407.6B
285.43%
42.99
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$40.6B
176.24%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$90.8B
85.35%
27.12
35.4%

Institutional Holdings

  • FMR Inc

    13.68%
  • BlackRock Inc

    5.88%
  • Alkeon Capital Management, LLC

    5.65%
  • Orbimed Advisors, LLC

    5.11%
  • T. Rowe Price Associates, Inc.

    4.28%
  • Vanguard Group Inc

    3.99%

Corporate Announcements

  • Keros Therapeutics Inc Earnings

    Keros Therapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

keros therapeutics, inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. the company's lead protein therapeutic product candidate is ker-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or mds, and in patients with myelofibrosis. it is also developing small molecule product candidate ker-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or fop, and is currently in a phase 1 clinical trial; and ker-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or pah. the company was founded i

Organization
Keros Therapeutics Inc
Employees
121
CEO
Dr. Jasbir S. Seehra Ph.D.
Industry
Commercial Services

FAQs